Johnson & Johnson

American multinational pharmaceutical and consumer goods company specializing in healthcare products, medical devices, and pharmaceuticals.

Company Type

public

Founded

1886

Headquarters

New Brunswick, New Jersey, USA

Stock

NYSE: JNJ

About Johnson & Johnson

Johnson & Johnson delivered exceptional 2025 results, with CEO Joaquin Duato describing it as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Q4 2025 reported sales grew 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Full-year 2025 sales reached $94.2 billion, up 6.0% year-over-year, demonstrating strong momentum across both business segments.

Financial Performance Overview shows Johnson & Johnson's remarkable growth trajectory. The company achieved extraordinary earnings growth with Q4 2025 EPS of $2.10 reported and $2.46 adjusted, while full-year 2025 EPS reached $11.03 reported and $10.79 adjusted. This performance reflects the effectiveness of Johnson & Johnson's strategic focus on innovation and operational excellence across its diverse healthcare portfolio.

Segment Performance demonstrated balanced growth across Johnson & Johnson's two main business segments. The Innovative Medicine segment achieved Q4 2025 sales of $15.8 billion, up 10.0% year-over-year with operational growth of 7.9%. The MedTech segment reached $8.8 billion in Q4 2025 sales, up 7.5% year-over-year with operational growth of 5.8%. For the full year, Innovative Medicine generated $60.4 billion in sales while MedTech contributed $33.8 billion, showing strong performance across pharmaceutical and medical device businesses.

Geographic Performance revealed robust growth across key markets. U.S. sales reached $14.2 billion in Q4 2025, up 7.5% year-over-year with operational growth of 7.5%. International markets achieved $10.4 billion in Q4 2025 sales, up 11.3% year-over-year with operational growth of 6.6%. For the full year, U.S. sales totaled $53.8 billion while international markets contributed $40.4 billion, demonstrating Johnson & Johnson's global reach and market penetration.

2026 Guidance reflects management confidence in continued growth momentum. Johnson & Johnson issued strong guidance for 2026, projecting estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance suggests continued strong performance across both Innovative Medicine and MedTech segments, supported by the company's robust pipeline and market-leading products.

Medical Innovation Achievements in 2025 were particularly noteworthy, highlighting Johnson & Johnson's leadership in developing breakthrough treatments. Significant innovations included the approval of CAPLYTA for major depressive disorder, representing a major advancement in mental health treatment. The company also secured approval for RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrating continued leadership in oncology therapeutics.

Landmark Clinical Data further strengthened Johnson & Johnson's market position. The company reported landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma. This clinical evidence supports Johnson & Johnson's position in treating complex hematological conditions and reinforces the company's reputation for developing innovative cancer therapies.

Strategic Acquisitions enhanced Johnson & Johnson's capabilities and pipeline strength. The acquisition of Halda Therapeutics during 2025 expanded the company's therapeutic capabilities and strengthened its pipeline of future medical breakthroughs across multiple therapeutic areas. This strategic acquisition demonstrates Johnson & Johnson's commitment to investing in innovative technologies and treatments that address unmet medical needs.

Surgical Technology Innovation marked Johnson & Johnson's expansion into advanced medical technology. The submission of the OTTAVA Robotic Surgical System represents the company's entry into the rapidly growing robotic surgery market, positioning Johnson & Johnson to compete with established players in minimally invasive surgical procedures. This innovation reflects the company's strategy of leveraging its medical expertise across multiple healthcare segments.

Operational Excellence contributed significantly to Johnson & Johnson's strong performance. The company achieved operational growth of 5.3% for the full year 2025, with adjusted operational growth of 4.2%, demonstrating effective management of costs and operational efficiency. This operational performance enabled Johnson & Johnson to convert revenue growth into strong earnings improvement and cash generation.

Research and Development Investment continued to drive Johnson & Johnson's innovation pipeline. The company's commitment to R&D investment, spending billions annually on pharmaceutical innovation and medical technology, has created a robust pipeline of future products across multiple therapeutic areas. This investment strategy has positioned Johnson & Johnson for sustained growth and market leadership in healthcare innovation.

Market Leadership Position was reinforced across multiple healthcare segments. Johnson & Johnson maintained dominant positions in oncology, immunology, neuroscience, cardiovascular, surgery, and vision care, with each of these six key therapeutic areas contributing to the company's overall growth and market presence. This diversified leadership reduces dependency on any single therapeutic area and provides multiple growth drivers.

Cash Generation and Financial Strength enabled Johnson & Johnson to pursue strategic initiatives while maintaining shareholder returns. The company generated approximately $19.7 billion in free cash flow for full year 2025, supporting strategic acquisitions, R&D investment, and capital returns to shareholders. This strong cash generation provides financial flexibility for future growth opportunities.

Regulatory Success in 2025 demonstrated Johnson & Johnson's ability to navigate complex regulatory environments and secure approvals for innovative treatments. The company's success in obtaining regulatory approvals for new indications and products reflects the strength of its clinical development programs and regulatory expertise.

Patient Impact remains central to Johnson & Johnson's mission and performance. The company's innovations in 2025, including new treatments for major depressive disorder and various cancers, directly impact patient lives and address critical unmet medical needs. This patient-centric approach drives both commercial success and fulfillment of Johnson & Johnson's broader healthcare mission.

Johnson & Johnson's 2025 performance demonstrates the effectiveness of its strategy focusing on medical innovation, operational excellence, and global market expansion. The combination of strong financial results, breakthrough innovations, and robust pipeline positions the company for continued leadership in the global healthcare industry.

History of Johnson & Johnson

Johnson & Johnson was founded in 1886 by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, establishing what would become one of the world's most influential healthcare companies. The company began with just 14 employees producing sterile surgical dressings in a former wallpaper factory in New Brunswick, New Jersey. Robert Wood Johnson's vision was revolutionary for its time - to create a company that would provide sterile surgical supplies to help prevent infections in medical procedures, addressing one of the most serious healthcare challenges of the late 19th century.

The company's first major innovation was the introduction of sterile surgical dressings and sutures, which significantly reduced surgical infection rates and transformed surgical practices. This breakthrough established Johnson & Johnson's reputation for innovation and medical excellence. Throughout the late 19th and early 20th centuries, the company expanded its product line to include baby products, first aid supplies, and over-the-counter medications, demonstrating an early understanding of diverse healthcare needs.

The iconic Johnson's Baby Powder was introduced in 1893 and became one of the company's most successful products, establishing Johnson & Johnson as a trusted name in baby care. This product exemplified the company's ability to identify and address specific consumer needs while maintaining high standards of safety and efficacy. The success of Johnson's Baby products laid the foundation for the company's future expansion into consumer healthcare.

20th Century Expansion transformed Johnson & Johnson from a specialized medical supply company into a global healthcare conglomerate. The company entered the pharmaceutical business in the 1930s, recognizing the growing importance of prescription medications in modern healthcare. This expansion into pharmaceuticals marked a significant strategic pivot that would eventually become the company's largest business segment.

The post-World War II period saw accelerated growth and diversification, with Johnson & Johnson expanding into medical devices and diagnostics. The company's ability to identify and enter new healthcare segments while maintaining excellence in existing operations became a hallmark of its strategic approach. This period also saw the formalization of Johnson & Johnson's famous credo, written by Robert Wood Johnson in 1943, which emphasized responsibility to customers, employees, communities, and shareholders.

Strategic Acquisitions in the late 20th and early 21st centuries significantly expanded Johnson & Johnson's capabilities and market presence. Major acquisitions included Neutrogena (1994), which brought dermatologist-recommended skincare products into the company's portfolio, and Aveeno (1999), adding natural skincare products using oat-based formulations. The 2006 acquisition of Pfizer Consumer Healthcare represented one of the largest consumer healthcare acquisitions in history, dramatically expanding Johnson & Johnson's over-the-counter medication portfolio.

Global Expansion has been central to Johnson & Johnson's growth strategy. The company now operates in over 60 countries with products sold in virtually every country worldwide. This global footprint provides Johnson & Johnson with access to diverse markets, regulatory environments, and patient populations, while also enabling the company to address global health challenges through its extensive distribution network.

Recent Strategic Evolution under CEO Joaquin Duato has focused on transforming Johnson & Johnson into a more innovation-driven healthcare company. Duato, who became CEO in 2022, has emphasized the company's strengths in six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. This strategic focus has led to what Duato called a "catapult year" in 2025, fueled by the strongest portfolio and pipeline in the company's history.

Medical Innovation Leadership has become increasingly central to Johnson & Johnson's identity and strategy. The company's 2025 achievements, including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrate its ability to develop breakthrough treatments that address critical unmet medical needs. These innovations build on Johnson & Johnson's long history of medical breakthroughs, from early sterile surgical dressings to modern biotechnology treatments.

Business Segment Evolution reflects Johnson & Johnson's adaptation to changing healthcare landscapes. The company now operates through two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). This structure allows Johnson & Johnson to leverage its expertise across different healthcare domains while maintaining focus on innovation and patient outcomes in each segment.

Regulatory Expertise has been developed over more than a century of operation in highly regulated healthcare markets. Johnson & Johnson's success in navigating complex regulatory environments and securing approvals for innovative treatments reflects the strength of its clinical development programs and regulatory expertise. This capability has become increasingly important as healthcare regulations have become more complex globally.

Corporate Responsibility has been integral to Johnson & Johnson's identity since its founding. The company's credo, emphasizing responsibility to all stakeholders, has guided its business decisions and community engagement for decades. This commitment to corporate responsibility has helped Johnson & Johnson maintain trust with patients, healthcare professionals, and regulators worldwide.

Technological Adaptation has been crucial to Johnson & Johnson's continued relevance and growth. From early adoption of sterile manufacturing techniques to modern investments in biotechnology, robotic surgery, and digital health solutions, the company has consistently embraced new technologies that can improve patient outcomes and operational efficiency.

Financial Strength has enabled Johnson & Johnson to pursue long-term strategic initiatives while maintaining stability through market cycles. The company's consistent revenue growth, strong cash generation, and investment in research and development have created a sustainable business model that can weather economic uncertainties while investing in future innovations.

As Johnson & Johnson approaches its 140th anniversary, the company continues to balance its heritage of innovation and patient care with the need to adapt to rapidly changing healthcare landscapes. The company's evolution from a small surgical dressing manufacturer to a global healthcare powerhouse demonstrates the importance of strategic vision, operational excellence, and unwavering commitment to improving human health.

Johnson & Johnson's history provides valuable lessons in building enduring success in the healthcare industry: the importance of innovation, the value of diversification across healthcare segments, the necessity of global reach, and the critical role of maintaining trust with all stakeholders. These principles continue to guide the company as it addresses the healthcare challenges of the 21st century.

Brands Owned by Johnson & Johnson

View all 15 brands

Johnson & Johnson owns 15 brands in our database. Showing featured brands below.

Acuvue

Owned by Johnson & Johnson

American brand of contact lenses and vision care products specializing in daily disposable and extended wear contact lenses, manufactured and marketed by Johnson & Johnson.

contact-lensesvision-careeye-care

Aveeno

Owned by Johnson & Johnson

American brand of skincare and hair care products specializing in natural ingredients and colloidal oatmeal formulations.

skincarenaturaloatmeal

Band-Aid

Owned by Johnson & Johnson

American brand of adhesive bandages and wound care products manufactured and marketed by Johnson & Johnson for minor cuts, scrapes, and injuries.

wound-careadhesive-bandagefirst-aid

Benadryl

Owned by Johnson & Johnson

American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.

antihistamineallergy-reliefcold-medicine

Carefree

Owned by Johnson & Johnson

American brand of feminine hygiene liners and pads, manufactured and marketed by Johnson & Johnson for daily feminine protection and menstrual care.

feminine-hygienelinersdaily-protection

Clean & Clear

Owned by Johnson & Johnson

American brand of acne treatment and skincare products specializing in oil-control and blemish-fighting formulations for teenagers and young adults.

acne-treatmentskincareoil-control

View all 15 brands owned by Johnson & Johnson

Shop Johnson & Johnson Brands

Disclosure: We may earn commission from purchases

Acuvue on Amazon

Aveeno on Amazon

Band-Aid on Amazon

Stock Information

Johnson & Johnson Ownership: Pros & Cons

Advantages

+Independent, publicly traded status ensures corporate governance and transparency with NYSE listing under JNJ
+Exceptional 2025 performance with Q4 sales growth of 9.1% to $24.6B exceeding expectations
+Strong 2026 guidance projecting $100.5B sales (6.7% growth at midpoint) and $11.53 adjusted EPS (6.9% growth)
+Diversified business model across Innovative Medicine ($60.4B) and MedTech ($33.8B) reduces market risk
+Breakthrough medical innovations including CAPLYTA for major depressive disorder approval
+Exceptional oncology leadership with RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer
+Landmark clinical data for TECVAYLI plus DARZALEX FASPRO for multiple myeloma treatment
+Global scale and market leadership across six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision
+Strong R&D pipeline with "game-changing science and technology" according to CEO Joaquin Duato
+Robust cash generation with ~$19.7B free cash flow supporting strategic acquisitions
+Strategic acquisition of Halda Therapeutics enhancing pipeline capabilities
+Surgical technology innovation with OTTAVA Robotic Surgical System submission
+Strong geographic performance with U.S. sales up 7.5% and international sales up 11.3% in Q4 2025
+Iconic consumer brands portfolio including Band-Aid, Tylenol, Johnson's Baby, Neutrogena, and Listerine

Considerations

-Regulatory scrutiny and complex approval processes for new pharmaceutical products across global markets
-Patent expirations and generic competition affecting established pharmaceutical products and revenue streams
-Healthcare policy changes and pricing pressure in key markets including U.S. and European healthcare systems
-Complex global supply chain requiring sophisticated logistics and quality control for medical products
-High R&D investment requirements with uncertain returns on experimental treatments and clinical trials
-Litigation risks associated with pharmaceutical products, medical devices, and consumer healthcare items
-Currency exchange rate impacts on international operations and financial reporting affecting earnings
-Competitive pressure from major pharmaceutical companies like Pfizer, Merck, Novartis, and Roche
-Medical device competition from Medtronic, Stryker, Boston Scientific, and Intuitive Surgical
-Consumer healthcare competition from Procter & Gamble, Reckitt Benckiser, and other consumer goods companies
-Operational complexity managing diverse business segments across pharmaceuticals, medical devices, and consumer products
-Regulatory compliance requirements across different countries and healthcare systems increasing operational costs
-Market access challenges in emerging markets with different healthcare infrastructure and reimbursement systems

Frequently Asked Questions About Johnson & Johnson

Is Johnson & Johnson publicly traded?

Yes, Johnson & Johnson is publicly traded on the New York Stock Exchange under the ticker symbol JNJ. The company has been publicly traded since 1944, providing liquidity for shareholders and enabling broad institutional ownership. JNJ is one of the most widely held healthcare stocks globally and is included in major stock market indices.

What were Johnson & Johnson's Q4 2025 financial results?

Johnson & Johnson reported Q4 2025 sales growth of 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. The company achieved EPS of $2.10 reported and $2.46 adjusted, demonstrating strong earnings growth and operational performance. Q4 results exceeded analyst expectations across both revenue and earnings metrics.

Who is Johnson & Johnson's CEO?

Joaquin Duato serves as Chairman and Chief Executive Officer of Johnson & Johnson. Duato has led the company's transformation into what he called a "catapult year" in 2025, focusing on medical innovation across six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. He became CEO in 2022 after serving in various leadership roles within the company.

When was Johnson & Johnson founded?

Johnson & Johnson was founded in 1886 by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. The company began with 14 employees producing sterile surgical dressings in New Brunswick, New Jersey, and has grown into a global healthcare powerhouse with operations in over 60 countries.

What is Johnson & Johnson's 2026 outlook?

Johnson & Johnson issued guidance for 2026 with estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). The company anticipates continued momentum in both Innovative Medicine and MedTech segments, supported by its robust pipeline and market-leading products.

How many people work at Johnson & Johnson?

Johnson & Johnson employs approximately 140,000 people worldwide across manufacturing, research, sales, and administrative functions. The company's global workforce serves healthcare professionals and patients in virtually every country worldwide, making it one of the largest employers in the healthcare industry.

What are Johnson & Johnson's main business segments?

Johnson & Johnson operates through two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Innovative Medicine develops prescription medicines across six key therapeutic areas and generated $60.4 billion in 2025 sales. MedTech produces surgical equipment, orthopedic devices, and medical technology solutions, contributing $33.8 billion in 2025 sales.

What medical innovations did Johnson & Johnson achieve in 2025?

Johnson & Johnson achieved several significant medical innovations in 2025, including the approval of CAPLYTA for major depressive disorder, approval of RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, and landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care for multiple myeloma. The company also acquired Halda Therapeutics and submitted the OTTAVA Robotic Surgical System.

What consumer brands does Johnson & Johnson own?

Johnson & Johnson owns iconic consumer brands including Band-Aid (adhesive bandages), Tylenol (pain reliever), Johnson's Baby (baby care products), Neutrogena (skincare), Aveeno (natural skincare), Listerine (mouthwash), Motrin (ibuprofen), Benadryl (allergy medicine), Zyrtec (allergy medicine), and Acuvue (contact lenses).

How is Johnson & Johnson performing in oncology?

Johnson & Johnson maintains exceptional oncology leadership with innovative treatments like RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer and landmark data for TECVAYLI plus DARZALEX FASPRO for multiple myeloma. The company's oncology portfolio represents a significant portion of its Innovative Medicine segment and continues to drive growth through breakthrough treatments.

What is Johnson & Johnson's position in medical devices?

Johnson & Johnson is a leader in medical devices through its MedTech segment, which generated $33.8 billion in 2025 sales. The company produces surgical equipment, orthopedic devices, and innovative medical technology solutions. Recent innovations include the OTTAVA Robotic Surgical System submission, positioning Johnson & Johnson in the advanced surgical technology market.

How does Johnson & Johnson invest in research and development?

Johnson & Johnson invests billions annually in research and development across pharmaceuticals and medical devices. The company's R&D investment has created the strongest portfolio and pipeline in its history, according to CEO Joaquin Duato. This investment focuses on six key therapeutic areas and drives the company's innovation leadership in healthcare.

What is Johnson & Johnson's global presence?

Johnson & Johnson operates in over 60 countries with products sold in virtually every country worldwide. The company maintains manufacturing facilities and research centers across every inhabited continent, with significant presence in developed markets and rapid expansion in emerging markets across Asia, Latin America, and Africa.

How does Johnson & Johnson approach corporate responsibility?

Johnson & Johnson's approach to corporate responsibility is guided by its credo, written by Robert Wood Johnson in 1943, which emphasizes responsibility to customers, employees, communities, and shareholders. The company maintains strong environmental, social, and governance initiatives and focuses on improving global health through its products and programs.

About Johnson & Johnson

History of Johnson & Johnson